Philogen completed the merger with Palio Ordinarie in a $596m deal.

Synopsis

Philogen, a biotech company that develops biotech products for the imaging and therapy of life, completed the merger with Palio Ordinarie in a $596m deal. This merger made it possible to dissolve the vehicle Palio Ordinarie, contributing towards the generation of a free float equal to 17% for the listing process.

Principals

target

PHILOGEN

bidder

Palio Ordinarie

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

dario neri

Co-Founder, Chief Executive Officer and CSO at PHILOGEN

Manager

target

Deal

£ 429 M

Total Value

Bidder Team (2)

franco barucci

Partner at Gatti Pavesi Bianchi Ludovici

Lawyer

bidder

Deals

£ 5.20 B

Total Value

vanesso sobrero

Partner at Gatti Pavesi Bianchi Ludovici

Lawyer

bidder

Deals

£ 561 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy